Filtered By:
Vaccination: Cancer Vaccines
Nutrition: Weight Loss
This page shows you your search results in order of date.
Order by Relevance | Date
Total 36 results found since Jan 2013.
Self-assembling Gn head ferritin nanoparticle vaccine provides full protection from lethal challenge of < em > Dabie bandavirus < /em > in aged ferrets
This study demonstrates that DBV GnH-FT nanoparticles provide an efficient vaccine efficacy in mouse and aged ferret models and should be an outstanding vaccine candidate targeted for the aged population against fatal DBV infection. IMPORTANCE Dabie bandavirus (DBV) is an emerging tick-borne virus that causes severe fever with thrombocytopenia syndrome (SFTS) in infected patients. Human SFTS symptoms progress from fever, fatigue, and muscle pain to the depletion of white blood cells and platelets with fatality rates up to 30%. The recent spread of its vector tick to over 20 states in the United States increases the potenti...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Dokyun Kim Eunha Kim Semi Kim Youseung Chung Chih-Jen Lai Inho Cha Sung-Dong Cho Yunseo Choi Xinghong Dai Stephanie Kim Seokmin Kang Mi-Jeong Kwak Ziyi Liu Younho Choi Su-Hyung Park Young Ki Choi Jae U Jung Source Type: research
The most common gastrointestinal alterations in patients with post-COVID syndrome
CONCLUSION: We identified female gender, obesity, cardiovascular diseases, cancer, hypertension and diabetes as major risk factors of post-COVID syndrome. Vaccinated status may prevent post-COVID gastrointestinal symptoms. Orv Hetil. 2023; 164(31): 1206-1212.PMID:37543972 | DOI:10.1556/650.2023.32839
Source: Orvosi Hetilap - August 6, 2023 Category: General Medicine Authors: Kata Angyal Anna Mandula Tajthy B álint Drácz P ál Miheller Mikl ós Horváth Hajnal Sz ékely Veronika Papp Di ána Czompa Attila Szij ártó Kl ára Werling Source Type: research
Fight Aging! Newsletter, July 10th 2023
In conclusion, the examination of the GBA can aid in understanding the etiology and development of NDs, which may benefit the improvement of clinical treatments for these disorders and ND interventions. This review indicates existing knowledge about the involvement of microbiota present in the gut in NDs and potential treatment options.
The Aging of the Enteric Nervous System
https://www.fightaging.org/archives/2023/07/the-aging-of-the-enteric-nervous-system/
The enteric nervous system is the nervous system of the intestines, and likely an important part of the relationship between the gut microbiome a...
Source: Fight Aging! - July 9, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
The Connection Between IBD and Aging
Inflammatory bowel disease (IBD) has long been thought of as an ailment of middle, or even young, adulthood. The chronic illness—which includes Crohn’s disease and ulcerative colitis, and can cause abdominal pain, diarrhea, bleeding, and decreased quality of life—impacts about 3.1 million people in the U.S. However, it is far from a disease only of the young and middle-aged. More than a quarter of people with IBD are elderly, a figure that is projected to climb to 30% by 2030, according to a 2021 Gastroenterology & Hepatology article.
Even more underappreciated is the growing population of people who ...
Source: TIME: Health - April 8, 2022 Category: Consumer Health News Authors: Katherine Harmon Courage Tags: Uncategorized Disease healthscienceclimate Source Type: news
Development and validation of a tool for evaluating YouTube-based medical videos
ConclusionCollectively, our findings indicated that the MQ-VET is a valid and reliable tool that will help to standardize future evaluations of online medical videos.
Source: Irish Journal of Medical Science - November 25, 2021 Category: General Medicine Source Type: research
